Korean J Physiol Pharmacol.  2012 Oct;16(5):321-326. 10.4196/kjpp.2012.16.5.321.

Antiproliferative and Cytotoxic Effects of Resveratrol in Mitochondria-Mediated Apoptosis in Rat B103 Neuroblastoma Cells

• Rahman MA
• Kim NH
• Kim SH
• Oh SM
• Huh SO

• KMID: 1493964
• DOI: http://doi.org/10.4196/kjpp.2012.16.5.321

Abstract

Resveratrol, a natural compound, has been shown to possess anti-cancer, anti-aging, anti-inflammatory, anti-microbial, and neuroprotective activities. In this study, we examined the antiproliferative and cytotoxicity properties of resveratrol in Rat B103 neuroblastoma cells; although it's molecular mechanisms for the biological effects are not fully defined. Here, we examined the cellular cytotoxicity of resveratrol by cell viability assay, antiproliferation by BrdU assay, DNA fragmentation by DNA ladder assay, activation of caspases and Bcl-2 family proteins were detected by western blot analyses. The results of our investigation suggest that resveratrol increased cellular cytotoxicity of Rat B103 neuroblastoma cells in a dose-and time-dependent manner with IC50 of 17.86 microM at 48 h. On the other hand, incubation of neuroblastoma cells with resveratrol resulted in S-phase cell cycle arrests which dose-dependently and significantly reduced BrdU positive cells through the downregulation of cyclin D1 protein. In addition, resveratrol dose-dependently and significantly downregulated the expression of anti-apoptotic protein includes Bcl-2, Bcl-xL and Mcl-1 and also activates cleavage caspase-9 and-3 via the downregulation of procaspase-9 and -3 in a dose-dependent manner which indicates that involvement of intrinsic mitochondria-mediated apoptotic pathway. In conclusion, resveratrol increases cellular cytotoxicity and inhibits the proliferation of B103 neuroblastoma cells by inducing mitochondria-mediated intrinsic caspase dependent pathway which suggests this natural compound could be used as therapeutic purposes for neuroblastoma malignancies.

Keyword

Apoptosis; Bcl-2 family; Cyclin D1; Neuroblastoma; Resveratrol

MeSH Terms

Animals
Apoptosis
Blotting, Western
Bromodeoxyuridine
Caspase 9
Caspases
Cell Cycle Checkpoints
Cell Survival
Cyclin D1
DNA
DNA Fragmentation
Down-Regulation
Hand
Humans
Inhibitory Concentration 50
Neuroblastoma
Proteins
Rats
Stilbenes
Bromodeoxyuridine
Caspase 9
Caspases
Cyclin D1
DNA
Proteins
Stilbenes

Figure

• 

  Fig. 1 Resveratrol increases cellular cytotoxicity of Rat B103 neuroblastoma cells. (A, B) B103 cells were cultured in 96-well culture dishes to near confluence 50~60% and then starved in DMEM containing 0.5% FBS for 24 h. Cell death was determined by using the cytotoxicity assay kit (CCK-8, Dojindo Lab). Cells were exposed to resveratrol in a different dose of 0 to 20 µM in dose dependent and 15 µM in time dependent experiments. Each point is mean±SEM of quintuple samples. Data are mean from three independent experiments in which the activity in the absence of resveratrol versus in the presence of resveratrol is significantly different (n=3, **p<0.01). (C) B103 cells were grown in 24-well culture dishes to near confluence 50% and then starved in DMEM containing 0.5% FBS for 24 h. They were then added 15 µM concentration of resveratrol and grown at 37℃, in humidified 5% CO2 for 48 h and then morphology was observed by Bright-Field Microscopy. Arrows indicate cells with apoptotic morphology. (D) B103 cells were grown in 100 mm culture dishes to near confluence 90% and then starved in DMEM containing 0.5% FBS for 24 h. The cells were then treated with 0, 15 and 20 µM of resveratrol. After 48 h resveratrol treatment, DNA was extracted and separated on 0.8% agarose gel containing ethidium bromide. DNA fragments were visualized under UV light. M indicates as a Marker. GA (Gambogic acid) used as a positive control.

• 

  Fig. 2 Antiproliferative effects resveratrol in DNA synthesis and cyclin D1 downregulation. (A) B103 cells were culture on a round cover slides in 24 well dishes until 80% confluence in 10% FBS. The cells were then treated in the absence and presence of 15 µM of resveratrol. After 46 h resveratrol treatment, cells were incubated with 10 µM BrdU for 2 h before fixation and subsequent immunostaining with an anti-BrdU antibody (Arrow shows BrdU positive cells). (B) The percentages of stained cells were counted in three independent random areas. Results are means±SE and representatives of three independent experiments are shown (n=3, *p<0.05). (C) B103 cells were cultured in 60-mm culture dishes to near 80% confluence in 10% FBS. They were treated with 0 to 20 µM of resveratrol for 48 h. Equal volumes of whole-cell extracts containing 40 µg of protein were separated and electrophoretically blotted. Cyclin D1 was detected via immunoblot analysis. β-actin was used as a loading control. (D) The intensities of the cyclin D1 bands were determined by densitometric scanning and analyzed by Bio-Profil software and the expression levels were normalized to β-actin. Results are mean±S.E. and representatives of three independent experiments are shown (n=3, *p<0.05, **p<0.01).

• 

  Fig. 3 Resveratrol down-regulates Bcl-2 family proteins. (A) B103 cells were cultured in 60-mm culture dishes to near 90% confluence and then starved in DMEM containing 0.5% FBS for 24 h. After 24 h starvation cells were treated with 0 to 20 µM of resveratrol. Whole cell lysates were subjected to 15% SDS-PAGE and the levels of Bcl-2, Bcl-xL, and Mcl-1 were detected by western blotting as described in materials and methods. β-actin was used as a loading control. (B~D) The intensities of the Bcl-2 bands, the Bcl-xL bands and the Mcl-1 bands were determined by densitometric scanning and analyzed by Bio-Profil software and the expression levels were normalized to β-actin. Results are mean±S.E. and representatives of three independent experiments are shown (n=3, *p<0.05, **p<0.01, ***p<0.001).

• 

  Fig. 4 Effects of resveratrol in caspase expression. (A) B103 cells were cultured in 60-mm culture dishes to near 90% confluence and then starved in DMEM containing 0.5% FBS for 24 h. They were treated with 0 to 20 µM of resveratrol for 48 h. Levels of caspase-9 and -3 proteins were detected by western blotting. β-actin was used as a loading control. (B, C) The intensities of the cleaved caspase-9 bands and the cleaved caspase-3 bands were determined by densitometric scanning and analyzed by Bio-Profil software and the expression levels were normalized to β-actin. Results are mean±S.E. and representatives of three independent experiments are shown (n=3, *p<0.05, **p<0.01). (D) B103 cells were cultured in 96-well dishes to near confluence 50~60% and then starved in DMEM containing 0.5% FBS for 24 h. After starvation cells were pretreated with 10 µM DEVD-FMK for 1 h just before exposure to 15 µM resveratrol for 48 h. Cell number was quantified by CCK-8 kit. Results are means±SE and representatives of three independent experiments are shown (n=3, *p<0.05).

Reference

1. Bénard J, Raguénez G, Kauffmann A, Valent A, Ripoche H, Joulin V, Job B, Danglot G, Cantais S, Robert T, Terrier-Lacombe MJ, Chassevent A, Koscielny S, Fischer M, Berthold F, Lipinski M, Tursz T, Dessen P, Lazar V, Valteau-Couanet D. MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Mol Oncol. 2008. 2:261–271.

2. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007. 369:2106–2120.

3. Castel V, Grau E, Noguera R, Martínez F. Molecular biology of neuroblastoma. Clin Transl Oncol. 2007. 9:478–483.

4. Shakibaei M, Harikumar KB, Aggarwal BB. Resveratrol addiction: to die or not to die. Mol Nutr Food Res. 2009. 53:115–128.

5. Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, Treon SP. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin Cancer Res. 2008. 14:1849–1858.

6. Pallàs M, Casadesús G, Smith MA, Coto-Montes A, Pelegri C, Vilaplana J, Camins A. Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection. Curr Neurovasc Res. 2009. 6:70–81.

7. Pallàs M, Verdaguer E, Tajes M, Gutierrez-Cuesta J, Camins A. Modulation of sirtuins: new targets for antiageing. Recent Pat CNS Drug Discov. 2008. 3:61–69.

8. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997. 275:218–220.

9. Pozo-Guisado E, Lorenzo-Benayas MJ, Fernández-Salguero PM. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int J Cancer. 2004. 109:167–173.

10. Komina O, Wesierska-Gadek J. Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells. Biochem Pharmacol. 2008. 76:1554–1562.

11. Roy P, Kalra N, Prasad S, George J, Shukla Y. Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharm Res. 2009. 26:211–217.

12. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004. 24:2783–2840.

13. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science. 1997. 278:1073–1077.

14. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, Kopelovich L, Hawk ET, Lieberman R, Lawrence JA, Ali I, Viner JL, Sigman CC. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr. 2000. 130:2S Suppl. 467S–471S.

15. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis. 2000. 21:525–530.

16. Clément MV, Hirpara JL, Chawdhury SH, Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood. 1998. 92:996–1002.

17. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem. 1997. 30:91–113.

18. Thorburn A. Death receptor-induced cell killing. Cell Signal. 2004. 16:139–144.

19. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene. 2004. 23:2950–2966.

20. Wolf BB, Green DR. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem. 1999. 274:20049–20052.

21. Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest. 2005. 115:2665–2672.

22. Surh Y. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res. 1999. 428:305–327.

23. Carbó N, Costelli P, Baccino FM, López-Soriano FJ, Argilés JM. Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun. 1999. 254:739–743.

24. Antonsson B, Martinou JC. The Bcl-2 protein family. Exp Cell Res. 2000. 256:50–57.

25. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999. 17:2941–2953.

26. Bertoncello I, Bradley TR, Watt SM. An improved negative immunomagnetic selection strategy for the purification of primitive hemopoietic cells from normal bone marrow. Exp Hematol. 1991. 19:95–100.

27. Buick RN, Till JE, McCulloch EA. Colony assay for proliferative blast cells circulating in myeloblastic leukaemia. Lancet. 1977. 1:862–863.

28. Minden MD, Buick RN, McCulloch EA. Separation of blast cell and T-lymphocyte progenitors in the blood of patients with acute myeloblastic leukemia. Blood. 1979. 54:186–195.

29. Datta R, Banach D, Kojima H, Talanian RV, Alnemri ES, Wong WW, Kufe DW. Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNAdamaging agents. Blood. 1996. 88:1936–1943.

30. Ibrado AM, Huang Y, Fang G, Liu L, Bhalla K. Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res. 1996. 56:4743–4748.